Key result
Dupilumab is linked to ~46% clinical remission in severe asthma, predicted by baseline LV-GLS.
Why the study?
Does dupilumab improve echocardiographic parameters and clinical remission in patients with severe type 2 asthma?
Observational
Does dupilumab improve echocardiographic parameters and clinical remission in patients with severe type 2 asthma?
Dupilumab may improve cardiac and pulmonary function in severe type 2 asthma, with baseline LV-GLS serving as a strong predictor of clinical remission.
Dupilumab was associated with improved cardiac strain in severe type 2 asthma; hypothesis-generating for CV benefits and remission prediction, requiring RCTs before practice change.
BACKGROUND: Severe asthma is characterized by impaired lung function and elevated cardiovascular risk. Type 2 inflammation, primarily mediated by IL-4 and IL-13, contributes to both airway and cardiac remodeling. Dupilumab, an IL-4Rα antagonist, has shown efficacy in improving respiratory outcomes; however, its impact on cardiac function remains insufficiently studied. OBJECTIVE: To assess the 12-month effects of dupilumab on echocardiographic parameters and evaluate its potential association with clinical remission in patients with severe type 2 asthma. METHODS: ≥ 80 % predicted. RESULTS: and FEF25-75, alongside reductions in residual volume and airway resistance. Clinical remission was achieved by 45.83 % of patients. Baseline LV-GLS emerged as a strong predictor of remission (AUC = 0.832), unlike RV-GLS (AUC = 0.545). CONCLUSIONS: Dupilumab markedly improved cardiac and pulmonary function and may promote clinical remission. Baseline LV-GLS may serve as a predictive marker, supporting cardiovascular assessment in asthma management.
No takes yet. Share an insight, caveat, or question.
Pelaia et al. (2026) conducted an observational in severe type 2 asthma. Dupilumab was evaluated on clinical remission. Dupilumab improved cardiac and pulmonary function in severe type 2 asthma, achieving clinical remission in 45.83% of patients, with baseline LV-GLS strongly predicting remission (AUC = 0.832).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: